Alshaikh Rasha A, Waeber Christian, Ryan Katie B
School of Pharmacy, University College Cork, Cork, Ireland.
School of Pharmacy, University College Cork, Cork, Ireland; Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland.
Adv Drug Deliv Rev. 2022 Aug;187:114342. doi: 10.1016/j.addr.2022.114342. Epub 2022 May 13.
There is an increasing momentum in research and pharmaceutical industry communities to design sustained, non-invasive delivery systems to treat chronic neovascular ocular diseases that affect the posterior segment of the eye including age-related macular degeneration and diabetic retinopathy. Current treatments include VEGF blockers, which have revolutionized the standard of care for patients, but their maximum therapeutic benefit is hampered by the need for recurrent and invasive administration procedures. Currently approved delivery systems intended to address these limitations exploit polymer technology to regulate drug release in a sustained manner. Here, we critically review sustained drug delivery approaches for the treatment of chronic neovascular diseases affecting the ocular posterior segment, with a special emphasis on novel and polymeric technologies spanning the spectrum of preclinical and clinical investigation, and those approved for treatment. The mechanism by which each formulation imparts sustained release, the impact of formulation characteristics on release and foreign body reaction, and special considerations related to the translation of these systems are discussed.
在研究和制药行业领域，设计持续、非侵入性给药系统以治疗影响眼后段的慢性新生血管性眼病（包括年龄相关性黄斑变性和糖尿病性视网膜病变）的势头日益增强。目前的治疗方法包括血管内皮生长因子（VEGF）阻滞剂，这彻底改变了患者的护理标准，但由于需要反复进行侵入性给药程序，其最大治疗益处受到阻碍。目前已批准的旨在解决这些局限性的给药系统利用聚合物技术以持续方式调节药物释放。在此，我们批判性地综述了用于治疗影响眼后段的慢性新生血管性疾病的持续给药方法，特别强调了跨越临床前和临床研究范围的新型和聚合物技术，以及那些已获批准用于治疗的技术。讨论了每种制剂实现持续释放的机制、制剂特性对释放和异物反应的影响，以及与这些系统转化相关的特殊考虑因素。
